Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Abstract
Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. ( …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
non-u.s. gov't
adult
female
male
aged
middle aged
young adult
80 and over
Clinical Trial
Phase III
Randomized Controlled Trial
Multicenter Study
Viral
Genotype
drug resistance
drug combinations
antiviral agents / therapeutic use*
chronic / complications
chronic / virology
antiviral agents / adverse effects
hepacivirus / genetics*
chronic / drug therapy*
investigators=[]
affs=[])
nezam afdhal
graham r foster
carbamates / adverse effects
carbamates / therapeutic use*
heterocyclic compounds
4 or more rings / adverse effects
4 or more rings / therapeutic use*
sofosbuvir / adverse effects
sofosbuvir / therapeutic use*
liver cirrhosis / etiology
viral nonstructural proteins / antagonists & inhibitors
pmid:26575258
doi:10.1056/nejmoa1512612
collabauthor(name='astral-3 investigators'
liver cirrhosis / drug therapy
Access
Citation
ID:
273036
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
273036
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet